PT - JOURNAL ARTICLE AU - Souhrid Mukherjee AU - Thomas A. Cassini AU - Ningning Hu AU - Tao Yang AU - Bian Li AU - Wangzhen Shen AU - Christopher W. Moth AU - David C. Rinker AU - Jonathan H. Sheehan AU - Joy D. Cogan AU - Undiagnosed Diseases Network AU - John H. Newman AU - Rizwan Hamid AU - Robert L. Macdonald AU - Dan M. Roden AU - Jens Meiler AU - Georg Kuenze AU - John A. Phillips III AU - John A. Capra TI - Personalized structural biology reveals the molecular mechanisms underlying heterogeneous epileptic phenotypes caused by <em>de novo</em> KCNC2 variants AID - 10.1101/2022.02.01.21268115 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.01.21268115 4099 - http://medrxiv.org/content/early/2022/02/02/2022.02.01.21268115.short 4100 - http://medrxiv.org/content/early/2022/02/02/2022.02.01.21268115.full AB - Background Next-generation whole exome sequencing (WES) is ubiquitous as an early step in the diagnosis of rare diseases and the interpretation of variants of unknown significance (VUS). Developmental and epileptic encephalopathies (DEE) are a group of rare devastating epilepsies, many of which have unknown causes. Increasing WES in the clinic has identified several rare monogenic DEEs caused by ion channel variants. However, WES often fails to provide actionable insight, due to the challenges of proposing functional hypotheses for candidate variants. Here, we describe a “personalized structural biology” (PSB) approach that addresses this challenge by leveraging recent innovations in the determination and analysis of protein 3D structures.Results We illustrate the power of the PSB approach in an individual from the Undiagnosed Diseases Network (UDN) with DEE symptoms who has a novel de novo VUS in KCNC2 (p.V469L), the gene that encodes the Kv3.2 voltage-gated potassium channel. A nearby KCNC2 variant (p.V471L) was recently suggested to cause DEE-like phenotypes. We find that both variants are located in the conserved hinge region of the S6 helix and likely to affect protein function. However, despite their proximity, computational structural modeling suggests that the V469L variant is likely to sterically block the channel pore, while the V471L variant is likely to stabilize the open state. Biochemical and electrophysiological analyses demonstrate heterogeneous loss-of-function and gain-of-function effects, respectively, as well as differential inhibition in response to 4-aminopyridine (4-AP) treatment. Using computational structural modeling and molecular dynamics simulations, we illustrate that the pore of the V469L variant is more constricted increasing the energetic barrier for K+ permeation, whereas the V471L variant stabilizes the open conformationConclusions Our results implicate KCNC2 as a causative gene for DEE and guided the interpretation of a UDN case. They further delineate the molecular basis for the heterogeneous clinical phenotypes resulting from two proximal pathogenic variants. This demonstrates how the PSB approach can provide an analytical framework for individualized hypothesis-driven interpretation of protein-coding VUS suspected to contribute to disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by awards from The National Institutes of Health (NIH) Common Fund, through the Office of Strategic Coordination and the Office of the NIH Director, to the clinical sites (U01HG007674 to Vanderbilt University Medical Center, U01HG010215-03S1 to Washington University). The work was also supported by NIH awards R01LM013434, and R01GM126249. It was also supported by a fellowship from the American Heart Association.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Vanderbilt University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.